• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
SG-DJ10 Capsule and Tablet Sample Checkweigher
NADP+
NMN
Ceritinib (LDK378) CAS:1032900-25-6
SG-JN10 0.1mg Tablet Capsule Check Weigher
β-Nicotinamide Adenine Dinucleotide (NAD+)

Lupin launches generic Vigamox Ophthalmic solution in the US

expressbpdJuly 06, 2017

Tag: lupin , Vigamox Ophthalmic solution , US

Lupin has announced the launch of its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5 per cent (base) having received an approval from the United States Food and Drug Administration (FDA) earlier. The launched product is from Lupin’s Pithampur manufacturing facility.

Lupin’s Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5 per cent (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.’s Vigamox Ophthalmic solution. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms.

Previous:Alzheimer's and Parkinson's spurred by same enzyme

Next:Granules India gets board nod to raise foreign investment limit

Related News

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Lupin launches generic Vigamox Ophthalmic solution in the US | Pharmasources.com

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board.

You may like
More>>

Tacrolimus Lactone Isomer (Iso-FK-506)

Tacrolimus Lactone Isomer (Iso-FK-506)
Orexin B (mouse)

Orexin B (mouse)
Cold Form Foil, Venus

Cold Form Foil, Venus
Praziquantel oral suspension 2.5%

Praziquantel oral suspension 2.5%
Astragalus Extract Powder 40%

Astragalus Extract Powder 40%
NICLOSAMIDE ANHYDROUS

NICLOSAMIDE ANHYDROUS
Organic Chaga Mushroom Extract

Organic Chaga Mushroom Extract
piperazineanhydrous

piperazineanhydrous
Hot Sale Rubus fruticosus extract

Hot Sale Rubus fruticosus extract
Citric Acid Anhydrous

Citric Acid Anhydrous

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service